Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07235293 · ClinicalTrials.gov registry record · Phase 2
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
A Phase 2 study of Colorectal Cancer, sponsored by Kahr Bio Australia Pty.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 16
- Study locations
NCT07235293: Recruiting Phase 2 study of Colorectal Cancer, sponsored by Kahr Bio Australia Pty.
NCT07235293 is a Phase 2 study of Colorectal Cancer that is actively recruiting participants, run by Kahr Bio Australia Pty. The registered enrollment target is 90 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (94% lower). The trial reports 16 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07235293, a Phase 2 study of Colorectal Cancer, is actively recruiting participants, sponsored by Kahr Bio Australia Pty.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 16
- Study locations
Study Summary
This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer.
Primary Outcome
Median Overall Survival (mOS) will be estimated using Kaplan-Meier methodology as the median time from the start of study treatment to the last known date a participant was alive. Censoring rules will be applied for participants without an event at the time of analysis, and 95% confidence intervals for mOS will be provided.
Conditions Studied
Interventions
- DRUG Fruquintinib
- DRUG DSP107 + Atezolizumab
Study Locations (16)
Victoria
- Monash Health - Clayton
- Footscray Hospital - Western Health - Footscray
- Austin Health - Heidelberg
- Alfred Health - Melbourne
- Sunshine Hospital - Western Health - Saint Albans
New South Wales
- Chris O'brien Lifehouse - Camperdown
- Westmead Hospital - Westmead
Colorado
- University of Colarodo Cancer Center - Aurora
Florida
- Mayo Clinic - Florida City
North Carolina
- Duke Cancer Institute - Duke Cancer Center - Durham
Pennsylvania
- UPMC Hillman Cancer Center - Pittsburgh
Texas
- The University of Texas MD Anderson Cancer Center - Texas City
Adelaide
- The Queen Elizabeth Hospital - Woodville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-01-20 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 2 |
What NCT07235293 shows while recruiting
NCT07235293 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Fruquintinib is the first listed.
NCT07235293 lists 16 locations in 11 states (Victoria, New South Wales, Colorado).
Frequently Asked Questions
What is clinical trial NCT07235293 about?
NCT07235293 is a clinical study titled "A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.". This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one ...
What is the current status of trial NCT07235293?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2026-01-20. Estimated completion is 2027-04-30.
What conditions does trial NCT07235293 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT07235293?
The interventions under investigation include: Fruquintinib (DRUG), DSP107 + Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT07235293?
This trial is sponsored by Kahr Bio Australia Pty, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07235293 being conducted?
This trial has 16 study locations across Colorado, Florida, North Carolina, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07235293's enrollment target sits among peer trials
90 225th of 381 higher than 156 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
RECRUITING · Phase 2
-
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
RECRUITING · Phase 2
-
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI